Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo de revisión (ReviewArticle)

Subclinical atherosclerosis and brain health in midlife: Rationale and design of the PESA-Brain study.

  • Tristão-Pereira, Catarina
  • Fuster, Valentin
  • Lopez-Jimenez, Alejandro
  • Fernández-Pena, Alberto
  • Semerano, Aurora
  • Fernandez-Nueda, Irene
  • Garcia-Lunar, Ines
  • Ayuso, Carmen
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
  • Tristão-Pereira, Catarina
  • Fuster, Valentin
  • Lopez-Jimenez, Alejandro
  • Fernández-Pena, Alberto
  • Semerano, Aurora
  • Fernandez-Nueda, Irene
  • Garcia-Lunar, Ines
  • Ayuso, Carmen
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Cognitive decline and dementia have been reportedly linked to atherosclerosis, the main cause of cardiovascular disease. Cohort studies identifying early brain alterations associated with subclinical atherosclerosis are warranted to understand the potential of prevention strategies before cerebral damage becomes symptomatic and irreversible. The Progression of Early Subclinical Atherosclerosis (PESA) study is a longitudinal observational cohort study that recruited 4,184 asymptomatic middle-aged individuals (40-54 years) in 2010 in Madrid (Spain) to thoroughly characterize subclinical atherosclerosis development over time. In this framework, the PESA-Brain study has been designed to identify early structural, functional and vascular brain changes associated with midlife atherosclerosis and cardiovascular risk factors. The PESA-Brain study targets 1,000 participants at the 10-year follow-up PESA visit and consists of thorough neuropsychological testing, advanced multimodal neuroimaging, and quantification of blood-based neuropathological biomarkers. We hypothesize that, in middle-age, the presence of cardiovascular risk factors and a high burden of subclinical atherosclerosis will be associated with structural, functional and vascular brain alterations, greater amyloid burden and subtle cognitive impairment. We further hypothesize that the link between subclinical atherosclerosis and poor brain health in midlife will be mediated by cerebrovascular pathology and intracranial atherosclerosis. Enrollment dates: The PESA-Brain study started in October 2020 and is estimated to be completed by December 2024. Conclusion: This study is in a unique position to unveil novel relationships between cardiovascular and brain alterations in the health-to-disease transition, which may have important implications for interventional and therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era

  • Porta-Pardo, Eduard|||0000-0001-7900-4239
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Godzik, Adam|||0000-0002-2425-852X
One of the key challenges of cancer biology is to catalogue and understand the somatic genomic alterations leading to cancer. Although alternative definitions and search methods have been developed to identify cancer driver genes and mutations, analyses of thousands of cancer genomes return a remarkably similar catalogue of around 300 genes that are mutated in at least one cancer type. Yet, many features of these genes and their role in cancer remain unclear, first and foremost when a somatic mutation is truly oncogenic. In this review, we first summarize some of the recent efforts in completing the catalogue of cancer driver genes. Then, we give an overview of different aspects that influence the oncogenicity of somatic mutations in the core cancer driver genes, including their interactions with the germline genome, other cancer driver mutations, the immune system, or their potential role in healthy tissues. In the coming years, this research holds promise to illuminate how, when, and why cancer driver genes and mutations are really drivers, and thereby move personalized cancer medicine and targeted therapies forward.